A federal court in New York has tossed a whistleblower lawsuit charging that large long-term care pharmacies violated the False Claims Act by failing to dispense requested generic drugs.
Long-term care pharmacy company PharMerica has agreed to pay about $213,000 to settle charges that it dispensed medications without prescriptions and committed other breaches of the Controlled Substances Act, federal authorities announced Wednesday.
Brookdale Senior Living has sued PharMerica, charging that the long-term care pharmacy improperly changed its drug pricing for Brookdale facilities.
Long-term care pharmacy giant PharMerica dispensed controlled narcotics without valid prescriptions and charged Medicare, the federal government alleges in a False Claims Act lawsuit. The company "vigorously" disputes the claims.
PharMerica has been charged in a False Claims Act lawsuit by the federal government.
Long-term care pharmacy company PharMerica dispensed controlled narcotics without valid prescriptions and billed Medicare for the drugs, the federal government has charged in a False Claims Act lawsuit.
Kindred Healthcare will split with PharMerica and instead partner with Omnicare in 2014, marking a significant change in the landscape of long-term care pharmacy services providers.
Kindred Healthcare will split with pharmacy partner PharMerica and join forces with Omnicare at the end of 2013, according to documents filed with the Securities and Exchange Commission.
Major long-term care provider Kindred Healthcare will split with its current pharmacy partner, PharMerica, and team with the sector's largest pharmacy, Omnicare, at the end of 2013, according to documents filed with the Securities and Exchange Commission.
MDI Achieve announced that MatrixCare is now integrated with several leading pharmacy service firms. These include Omnicare, PharMerica, and FrameworkLTC.
The parent company of Golden Living officially launched AlixaRx with predictions it could become a $250 million per year business within 18 months.
Executives tied to one of the nation's largest nursing home chains say a new institutional pharmacy model they unveiled this week could soon become the market's No. 3 player. The parent group of Golden Living officially launched AlixaRx this week with predictions it could become a $250 million per year business within 18 months.
Omnicare has officially ended its attempt to absorb PharMerica Corp. The reversal comes less than a month after federal regulators attempted to block the deal. Officials said the merger would have created an institutional pharmacy company that reaches nearly 60% of the nation's nursing home beds. PharMerica has repeatedly tried to prevent the takeover since it was announced last year. PharMerica countered that the offer was insufficient and was unlikely to survive antitrust scrutiny.
Leading long-term care pharmacy provider Omnicare, which announced this week that it has ended its efforts to takeover competitor PharMerica, posted a profit in the fourth quarter.
Omnicare announced Monday that it is extending its offer to purchase all outstanding shares of rival PharMerica for $15 per share to Jan. 20. The original offer was scheduled to expire Dec. 2.
A proposed regulation that would require nursing homes to hire independent pharmacists to oversee residents' medication plan regimens could have a huge impact on pharmacy services suppliers such as Omnicare and PharMerica.
Omnicare has filed a lawsuit in hopes of making PharMerica accept a $440 million purchase offer and halt a poison pill anti-takeover defense.
Omnicare's top management decided private negotiations with their counterparts at takeover target PharMerica were not working. So on Tuesday, Omnicare went public with an announced $15 per share bid for the company. The proposed deal would involve the No. 1 institutional pharmacy provider purchasing the No. 2 for $715 million, according to an Omnicare announcement.
Omnicare, the biggest institutional pharmacy provider in the long-term care sector, publicly announced a $715 million bid for top rival PharMerica on Tuesday. Dissatisfied with the outcome of behind-doors talks over the past four months, Omnicare leaders decided to take their case directly to PharMerica board members.